First, they could be followed

for at least 6 months after the initiation of treatment. Second, they had proteinuria in excess of 3.5 g/day and serum albumin concentrations of <3.0 g/dl at the start of treatment. Third, MCNS was diagnosed pathologically by light microscopic findings, and confirmed by negative immunofluorescence and typical ultrastructural morphology. Fourth, patients were not treated with corticosteroids or cytotoxic agents. This study was approved by the IRB/Ethics Committee of Yokohama City University see more Medical Center (D-1309006). Therapies and measurements Three groups were included in the present study and were listed in Table 1. Pretreatment baseline parameters, including creatinine clearance, estimated glomerular filtration rate (eGFR), urinary protein excretion, serum total cholesterol concentration, serum albumin concentration, and serum hemoglobin concentration were measured. After discharge, blood pressure, urinary protein excretion, and serum creatinine levels were monitored on an outpatient basis every 2–4 weeks. The adverse effects of cyclosporine and prednisolone were monitored based on medical records. The selectivity index was calculated as the clearance of IgG divided by the clearance of transferrin.

All patients were instructed to follow a low-sodium diet (5 g/day). Patients with marked edema were LY2603618 clinical trial administered furosemide orally or intravenously, and few patients received intravenous selleck chemical albumin. Table 1 Treatment groups Group 1 Patients received cyclosporine (2–3 mg/kg/day) and intravenous methylprednisolone pulse therapy (0.5 or 1.0 g/day DCLK1 for 3 days), which were followed by the oral administration of prednisolone (initial doses 30 mg/day). The dose of cyclosporine was maintained at whole-blood trough levels between 50 and 150 ng/ml until the end of the first 6-month

treatment period Group 2 Patients received intravenous methylprednisolone pulse therapy (0.5 or 1.0 g/day for 3 days) followed by the oral administration of prednisolone (initial doses 0.4–0.8 mg/kg/day) Group 3 Patients received oral prednisolone alone (initial doses 0.6–1.0 mg/kg/day) Definitions of remission The response of treatment in nephrotic syndrome was categorized as complete remission, partial remission, or no response. Complete remission was defined as a reduction in proteinuria to below 300 mg/day for three consecutive days. Partial remission was defined as proteinuria of over 300 mg/day, but below 3.5 g/day. No response was defined as proteinuria of more than 3.5 g/day. The relapse of nephrotic syndrome was defined as proteinuria in excess of 1 g/day that lasted for more than three consecutive days during the follow-up.